Obinutuzumab Effective in Follicular Lymphoma, but at a Cost [News in Brief]

Anti-CD20 antibody outperforms rituximab—although side effects more frequent, serious.

from Cancer via ola Kala on Inoreader http://ift.tt/2zNoAeA
via IFTTT